Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Sep 20:2016:bcr2016216880.
doi: 10.1136/bcr-2016-216880.

Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma

Kazuyo Nagashima  1 , Hiroaki Tanaka  2 , Yurie Nagai  2 , Yasumasa Sugita  2
Affiliations
Case Reports

Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma

Kazuyo Nagashima et al. BMJ Case Rep. .

Abstract

During treatment for malignant lymphoma, cytopenia can develop for several reasons. In the treatment of cytopenia, various possibilities should be considered because inadequate treatment causes exacerbation of cytopenia and can lead to fatal conditions, such as infection and bleeding. Herein, we describe immune pancytopenia 3 months after the last exposure to chemotherapy in a patient with diffuse large B-cell lymphoma (DLBCL). She suffered from severe pancytopenia after two courses of rituximab and bendamustine therapy for a second relapse of DLBCL. Immune pancytopenia was diagnosed with bone marrow tests and the presence of autoantibodies; it promptly resolved after initiation of prednisolone therapy. Clinicians should be aware of immune cytopenia and monitor for it carefully, even if patients have already finished chemotherapy treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical course. WBC, white cell count; Plt, platelet; Hb, haemoglobin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dührsen U, Augener W, Zwingers T et al. . Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987;67:235–9. 10.1111/j.1365-2141.1987.tb02333.x - DOI - PubMed
    1. Economopoulos T, Stathakis N, Constantinidou M et al. . Cold agglutinin disease in non-Hodgkin's lymphoma. Eur J Haematol 1995;55:69–71. 10.1111/j.1600-0609.1995.tb00241.x - DOI - PubMed
    1. Jones SE. Autoimmune disorders and malignant lymphoma. Cancer 1973;31:1092–8. 10.1002/1097-0142(197305)31:5<1092::AID-CNCR2820310509>3.0.CO;2-B - DOI - PubMed
    1. Grønbaek K, D'Amore F, Schmidt K. Autoimmune phenomena in non-Hodgkin's lymphoma. Leuk Lymphoma 1995;18:311–6. 10.3109/10428199509059623 - DOI - PubMed
    1. Váróczy L, Gergely L, Zeher M et al. . Malignant lymphoma-associated autoimmune diseases—a descriptive epidemiological study. Rheumatol Int 2002;22:233–7. 10.1007/s00296-002-0229-4 - DOI - PubMed

Publication types

MeSH terms